Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Flotetuzumab, RUO) (HB714046)

Name: Anti-Human IL-3R alpha/CD123 & CD3 epsilon Bispecific Reference Antibody (Flotetuzumab, RUO)
Brand: abinScience
SKU: HB714046
Price: 320 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HB714046
説明	Flotetuzumab (HB714046) is a research-grade recombinant antibody targeting CD123. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	VH-VL-VH'-VL'
発現システム	Mammalian cells
ターゲット	IL-3R subunit alpha, IL-3 receptor subunit alpha, CD123, Interleukin-3 receptor subunit alpha, IL3R, IL-3R-alpha, IL3RA, IL-3RA, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
エンドトキシンレベル	< 10 EU/mg
純度	>95% purity as determined by SDS-PAGE.
精製	Purified by Nickel column.
アクセッション番号	P26951 & P07766
形態	Liquid
保存バッファー	0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	Bispecific, MGD-006, MGD006, RES234, S80880, 1664355-28-5
背景	Vibecotamab (XmAb®14045) is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.
注意事項	For research use only. Not suitable for clinical or therapeutic use.